Use of neuromuscular blockers in the critical patient;Utilización de bloqueantes neuromusculares en el paciente crítico

Medicina Intensiva

Volumn 32, Issue SUPPL. 1, 2008, Pages 69-76

  Sandiumenge, A ^a   Angles R ^b   Martinez Melgar J L ^c   Torrado, H ^d  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL MONTECELO   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Critically ill patient; ICU; Monitoring; Neuromuscular blockers; Recommendation

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANXIOLYTIC AGENT; ATRACURIUM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISATRACURIUM; CLINDAMYCIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANTROLENE; DIURETIC AGENT; EPHEDRINE; FUROSEMIDE; GLYCERYL TRINITRATE; IMMUNOSUPPRESSIVE AGENT; LIDOCAINE; LITHIUM; MAGNESIUM; METRONIDAZOLE; MIVACURIUM; NARCOTIC AGENT; NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM; SALBUTAMOL; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN; VASODILATOR AGENT; VECURONIUM;

ANALGESIA; ARTIFICIAL VENTILATION; ASTHMATIC STATE; CLINICAL PROTOCOL; CRITICALLY ILL PATIENT; DRUG ELIMINATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG USE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; INTRACRANIAL HYPERTENSION; KIDNEY METABOLISM; LIVER METABOLISM; MUSCLE TONE; NEUROMUSCULAR BLOCKING; OPERATING ROOM; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PATIENT MONITORING; RESPIRATORY DISTRESS SYNDROME; REVIEW; SEDATION;

ALGORITHMS; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE UNITS; MONITORING, PHYSIOLOGIC; NEUROMUSCULAR BLOCKING AGENTS; OXYGEN CONSUMPTION;

EID: 45749107611     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Arroliga A, Frutos-Vivar F, Hall J, Esteban A, Apezteguía C, Soto L, et al; International Mechanical Ventilation Study Group. Use of the sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest. 2005;128:496-506.
2. Sánchez-Izquierdo JA, Alted E, Borges MSA, Sandiumenge A. Sedo-analgesia en la Unidad de Cuidados Intensivos. Situación en España. Med Intensiva. 1998;22:11-6.
3. Murray MJ, Cowen J, DeBlock H, Erstad B, Gray AW, Tescher AN, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2002;30:142-56.
4. Brower RG, Fessler HE. Mechanical ventilation in acute lung injury and acute respiratory distress syndrome. Clin Chest Med. 2000;21:491-510.
5. Lee DL, Chiang HT, Lin SL, Ger LP, Kun MH, Huang YCT. Prone position ventilation induces sustained improvement in oxygenation in patients with acute respiratory distress syndrome who have a large shunt. Crit Care Med. 2002;30:1446-56.
6. Brower RG, Ware LB, Berthiaume Y, Matthay MA. Treatment of ARDS. Chest. 2001;120:1347-67.
7. Sessler CN. Sedation, analgesia and neuromuscular blockade for high-frequency oscillatory ventilation. Crit Care Med. 2005;33:S209-16.
8. Forel JM, Roch A, Marin V, Michelet P, Demory D, Blache JL, et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2006;34:2749-57.
9. Gainnier M, Roch A, Forel JM, Thirion X, Arnal JM, Donati S, et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2004;32:113-9.
10. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults. A review. Chest. 2004;125:1081-102.
11. Adnet F, Dhissi G, Barron SW, Galinski M, Rayeh F, Cupa M, et al. Complication profiles of adult asthmatics requiring paralysis during mechanical ventilation. Intensive Care Med. 2001;27:1729-36.
12. Spagnolo SV. Status asthmaticus and hospital management of asthma. Immunol Allergy Clin North Am. 2001;21:503-33.
13. Werba A, Klezl M, Shramm W. The level of neuromuscular block needed to suppress diaphragmatic movement during tracheal suction in patients with raised intracranial pressure: A study with vecuronium and atracuriium. Anaesthesia. 1993;48:301-3.
14. Wilson JA, Branch CL. Neuromuscular blockade in head-injured patients with increased intracranial pressure: continuos vs intermittent use. J Neurosurg Anesthesiol. 1994;2:139-41.
15. Prielipp RC, Coursin DB. Sedative and neuromuscular blocking drug use in critically ill patients with head injury. New horizons. 1995;3:456-68.
16. Marik PE, Varon J, Trask T. Management of head trauma. Chest. 2002;12:699-711.
17. Guha A. Management of traumatic brain injury: some current evidence and applications. Postgrad Med J. 2004;80:650-3.
18. Manthous CA, Hall JB, Kushner R, Schmidt GA, Russo G, Wood LDH. The effect of mechanical ventilation on oxygen consumption in critically ill patients. Am J Respir Crit Care Med. 1995;151:210-4.
19. Irish CL, Murkin JM, Clealand A, MacDonald JL, Mayer R. Neuromuscular blockade significantly decreases systemic oxygen consumption during hypothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1991;5:132-4.
20. Freebairn RC, Derrick J, Gomersall CD, Young RJ, Joynt GM. Oxygen delivery, oxygen consumption and gastric intramucosal pH are not improved by computer-controlled closed-loop vecuronium infusion in severe sepsis and septic shock. Crit Care Med. 1997;25:72-7.
21. Russell WC, Greer R, Harper NJ. The effect of neuromuscular blockade on oxygen supply, consumption and total chest compliance in patients with high oxygen requirements undergoing mechanical ventilation. Anesth Intensive Care. 2002;30:192-7.
22. Eastwood NB, Boyd AH, Parker CJ, Hunter JM. Pharmacokinetics of 1R-cis 1'R-cis atracurium besylate (51w89) and plasma laudanosine concentrations in health and chronic renal failure. Br J Anaesth. 1995;75:431-5.
23. Lui PW, Ma JY, Chan KK. Modification of tonic-clonic convulsions by atracurium in multiple-monitored electroconvulsive therapy. J Clin Anesth. 1993;5:16-21.
24. Isenstein DA, Venner DS, Duggan J. Neuromuscular blockade in the Intensive Care Unit. Chest. 1992;102:1258-66.
25. Bunch TJ, Thalji MK, Pellikka PA, Aksamit JR. Respiratory failure in tetanus: case report and review of a 25-year experience. Chest. 2002;122:1488-92.
26. Carbone JR. The neuroleptic malignant and serotonin syndroms. Emerg Med Clin North Am. 2000;18:317-25.
27. Chamorro C, Romera MA, Pardo C, Silva JA. Nuevos bloqueadores neuromusculares. Med Intensiva. 2001;25:340-3.
28. Vandenbrom RHG, Wierda JM. Pancuronium bromide in the intensive care unit: a case of overdose. Anesthesiology. 1998;69:996-7.
29. Van Miert MM, Eastwood BN, Boyd AH, Parker CJ, Hunter JM. The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. Br J Pharmacol. 1997;44:139-44.
30. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, et al. Reversal of Rocuronium-induced Neuromuscular Block by the Selective Relaxant Binding Agent Sugammadex. Dose-finding and Safety Study. Anesthesiology. 2006;104:667-74.
31. Segredo V, Caldwell J, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med. 1992;327:524-8.
32. Dhonneur G, Cerf C, Lagneau F, Mantz J, Gillotin C, Duvaldestin P. The pharmacokinetics of cisatracuruium in patients with acute respiratory distress syndrome. Anesth-Analg. 2001;93:400-4.
33. Loper KA, Butler S, Nessly M, Wild L. Paralyzed with pain: the need for education. Pain. 1989;37:315-6.
34. Blackburn P, Vissers R. Pharmacology of emergency Department pain management and Conscious sedation. Emerg Med Clin Norh Am. 2000;18:803-27.
35. Terai T, Yukioka H, Asada A. Pain evaluation in the intensive care unit: observer-reported faces scale compared with self reported visual analoge scal. Reg Anesth Pain Med. 1998;23:147-51.
36. Ono K, Ohta Y, Nagano O, Aziz L, Hirakawa M. Acid base changes and muscle relaxants. Masui. 1996;45:2-14.
37. Hunter JM. Resistance to non-depolarizing neuromuscular bloquing agents. Br J Anaesth. 1991;67:511-4.
38. Walting SM, Dasta JF. Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med. 1994;22:884-93.
39. Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: Clinical and pathologic aspects. Ann Neurol. 1996;40:645-54.
40. Larsson L, Li X, Edström L, Eriksson LI, Zackrisson H, Argentini C, et al. Acute quadriplegia and loss of muscule myosisn in patients treated with non-depolarizing neuromuscular blocking agents and corticosteroids: mechanisms at the cellular and molecular levels. Crit Care Med. 2000;28:34-45.
41. DuBois DC, Almon RR. A possible role for glucocorticoids in denervation atrophy. Muscle Nerve. 1991;14:1131-9.
42. Tavernier B, Rannou JJ, Vallet B. Peripheral nerve stimulation and clinical assestment for dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med. 1998;26:804-5.
43. Frankel H, Jeng J, Tilly E, St Andre A, Champion H. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit. Am Surg. 1996;62:503-6.
44. Strange C, Vaughan L, Franklin C, Johnson J. Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Respir Crit Care Med. 1997;156:1556-61.
45. Rudis MI, Sikora CA, Angus E, Peterson E, Popovich J Jr, Hyzy R, et al. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med. 1997;4:575-83.
46. Deem S, Lee C, Curtis JR. Acquired neuromuscular disorders in the intensive care unit. Am J Respir Crit Care Med. 2003;168:735-9.